This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The expanding applications of long-read sequencing, which provide more detailed and accurate insights into complex genetic information, further drive market growth. In addition, government investments and initiatives in genome sequencing projects across Europe have significantly boosted accessibility and adoption.
As the area keeps its attention on developments in healthcare and precision medicine, genome sequencing is becoming a critical tool for improving diagnostics, personalized treatments, and disease prevention. These trends are set to shape the future of the genome sequencing market in Europe, ensuring continued innovation and wider consumer access.
Market Introduction
The growing demand for genetic testing, the growing use of precision medicine, and improvements in sequencing technologies are all contributing to the notable growth of the European genome sequencing market. An increasingly important tool in research, diagnostics, and individualized healthcare is genome sequencing, which decodes an organism's entire DNA sequence.As next-generation sequencing (NGS) becomes more widely available and sequencing costs decline, the technology becomes more accessible, facilitating its integration into European healthcare systems. Prenatal and neonatal screening, cancer diagnosis, rare disease detection, and pharmacogenomics are important uses.
The market is being further stimulated by government programs and investments in genomic research projects, such as the UK's 100,000 Genomes Project. More precise and thorough genetic analysis is now possible thanks to the growing use of long-read sequencing technologies, improving clinical outcomes.
As Europe continues to prioritize innovation in healthcare, the genome sequencing market is set to play a pivotal role in advancing medical research and delivering personalized treatments.
Market Segmentation
Segmentation 1: by Product
- Kits
- Instruments
- Software
Segmentation 2: by End User
- Pharmaceutical and Biotechnology Companies
- Hospitals and Diagnostic Laboratories
- Population Sequencing Organizations
- Research and Academic Institutes
- Others
Segmentation 3: by Region
- Europe: Germany, U.K., Spain, Italy, and France, and Rest-of-Europe
How can this report add value to an organization?
Product/Innovation Strategy: The Europe genome sequencing market has been segmented based on various categories, such as by product, end user, and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.Competitive Strategy: The Europe genome sequencing market is a highly fragmented market, with many public and few private companies. Key players in the genome sequencing market analyzed and profiled in the study involve established players that offer various kinds of products.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.Some prominent names established in this market are:
- Eurofins Scientific S.E.
- F. Hoffmann-La Roche Ltd.
- OncoDNA
- Oxford Nanopore Technologies plc
- QIAGEN N.V.
This product will be delivered within 3-5 business days.
Table of Contents
Companies Mentioned
- Eurofins Scientific S.E.
- F. Hoffmann-La Roche Ltd.
- OncoDNA
- Oxford Nanopore Technologies plc
- QIAGEN N.V.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 67 |
Published | January 2025 |
Forecast Period | 2024 - 2033 |
Estimated Market Value ( USD | $ 2.22 Billion |
Forecasted Market Value ( USD | $ 7.23 Billion |
Compound Annual Growth Rate | 14.0% |
Regions Covered | Europe |
No. of Companies Mentioned | 5 |